ESMO publishes updated guidelines on cancer careJuly 09, 2010
Enhanced and revised documents provide vital, evidence-based information for treating cancer
The European Society for Medical Oncology (ESMO) just released an enhanced and revised set of clinical recommendations designed to help oncologists deliver the best quality care to their patients.
The ESMO Clinical Practice Guidelines (CPG) offer vital, evidence-based information including the incidence of the malignancy, diagnostic criteria, staging of disease and risk assessment, treatment plans and follow-up.
Formerly known as the ESMO Clinical Recommendations, the ESMO Clinical Practice Guidelines are intended to provide users with a set of requirements for the highest standard of care for cancer patients.
"The Clinical Practice Guidelines are central to ESMO's mission, which is to advance cancer care and cure through fostering and disseminating good science that leads to better medicine and determines best practice," said ESMO President Prof David Kerr.
A growing number of the new guidelines have been developed using large, multidisciplinary writing groups, ensuring optimal input from the oncology profession and a better geographic representation.
"ESMO is constantly striving to improve the care of cancer patients worldwide," said Prof Kerr. "By developing these new guidelines with the assistance of a wide range of clinicians we can help share the joint expertise of the world's best doctors from many disciplines."
The ESMO Clinical Practice Guidelines include guidelines for breast cancer, colorectal cancer and non-small-cell lung cancer that have been expanded to include more treatment details and further discussion of the importance of multidisciplinary plans for particular patient settings.
Lung cancer is now dealt with in two distinct guidelines, one covering early and locally-advanced cancer, while the other focuses on metastatic disease.
One new guideline is focused specifically on cardiotoxicity, a potential side-effect of some chemotherapeutic agents.
Four further guidelines have been rewritten, drawing on the knowledge of the global oncology community. These include guidelines on soft tissue sarcoma and bone sarcoma, and a guideline on the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting.
The guideline on the prevention of chemotherapy- and radiotherapy-induced nausea was developed as the result of the 3rd Perugia Consensus Conference organized by the Multinational Association of Supportive Care in Cancer (MASCC) and ESMO.
"ESMO is striving to further increase the value of its guidelines by introducing a more multidisciplinary approach in their development, not only through the use of physical meetings but also through the ESMO Professional Networking Community," said Prof Kerr.
Other guidelines have also been reviewed:
* Pancreatic cancer: including more detail relating to treatment planning in all stages of the disease.
* epatacellular cancer: including an expanded section in surgical and medical treatment, especially targeted therapy.
* Multiple myeloma: revised according to new drug indications.
* Gastrointestinal stromal tumors (GIST): revised with more treatment-orientated details.
* Cancer, fertility and pregnancy: including more information on treatment, especially surgery and highlighting problems of breast, cervical and myeloma cancer in pregnancy as well as further details about delivery of chemotherapy, hormonal and targeted therapy, radiotherapy and supportive agents in pregnant women with cancer.
* Endometrial cancer: including a new section of histology and further guidance on treatment options in these settings.
* Management of febrile neutropenia: including more detail on treatment assessments and how to manage patients.
The new guidelines published in June represent the first stage of a process that will include guidelines for more than 55 different clinical situations, covering almost all tumor types as well as various other topics, including the therapeutic use of growth factors.
European Society for Medical Oncology
Related Clinical Practice Current Events and Clinical Practice News Articles
Genetic marker associated with risk for pulmonary fibrosis
New research from Brigham and Women's Hospital (BWH) finds that a genetic risk factor for pulmonary fibrosis, an uncommon but deadly lung disease, may be effective in identifying individuals at risk for this disease.
Researchers find genetic risk factor for pulmonary fibrosis
A paper recently published in the New England Journal of Medicine and co-written by physicians and scientists at the University of Colorado School of Medicine finds that an important genetic risk factor for pulmonary fibrosis can be used to identify individuals at risk for this deadly lung disease.
Researchers find genetic tie to improved survival time for pulmonary fibrosis
Research into genetic features of pulmonary fibrosis by physicians and scientists at the University of Colorado School of Medicine may lead to improved treatment of this deadly lung disease, according to a paper published online by JAMA.
Rotavirus vaccine developed in India demonstrates strong efficacy
The Government of India's Department of Biotechnology (DBT) and Bharat Biotech announced positive results from a Phase III clinical trial of a rotavirus vaccine developed and manufactured in India.
Variations in antibiotic prescribing of acute rhinosinusitis in united states ambulatory settings
Antibiotics for acute rhinosinusitis (ARS) are prescribed frequently- especially for younger adult patients and in primary care settings-despite recent consensus guidelines that discourage antibiotic use in mild cases, according to a study in the May 2013 issue of Otolaryngology-Head and Neck Surgery.
Geneticists find causes for severe childhood epilepsies
Researchers at the University of Arizona have successfully determined the genetic mutations causing severe epilepsies in seven out of 10 children for whom the cause of the disorder could not be determined clinically or by conventional genetic testing.
Study confirms everolimus can overcome trastuzumab resistance in HER-2 positive early breast cancer
A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab has left researchers contemplating a puzzle.
Breast cancer heterogeneity no barrier to predictive testing, study shows
Breast cancers contain many different cell types with different patterns of gene expression, but a new study provides reassurance that this variability should not be a barrier to using gene expression tests to help tailor cancer treatments to individual patients.
Big-Data Analysis Identifies Prognostic RNA Markers in a Common Form of Breast Cancer
A Big-Data analysis that integrates three large sets of genomic data available through The Cancer Genome Atlas has identified 37 RNA molecules that might predict survival in patients with the most common form of breast cancer.
Frequently used biologic agents might cause acute liver injury
A commonly used class of biologic response modifying drugs can cause acute liver injury with elevated liver enzymes, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.
More Clinical Practice Current Events and Clinical Practice News Articles